Abstract
Objectives: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. Methods: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Results: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number
Original language | English |
---|---|
Pages (from-to) | 193-199 |
Number of pages | 7 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 68 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2013 |
Keywords
- Antiretroviral therapy
- CD4 response
- Darunavir
- Etravirine
- HBV
- HCV
- HIV resistance
- HIV-1
- Integrase inhibitors
- Liver disease
- Maraviroc
- Viral hepatitis
- Viral load
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases